参考文献/References:
[1]Neumann FJ,Sousa-Uva M,Ahlsson A,et al. 2018 ESC/EACTS Guidelines on myocardial revascularization[J]. Eur Heart J,2019,40(2):87-165.
[2]Yusuf S,Zhao F,Mehta SR,et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation[J]. N Engl J Med,2001,16,345(7):494-502.
[3]Steinhubl SR,Berger PB,Mann JT 3rd,et al. Clopidogrel for the Reduction of Events During Observation. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention:a randomized controlled trial[J]. JAMA,2002,288(19):2411-2420.
[4]Valgimigli M,Bueno H,Byrne RA,et al. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS:The Task Forcefor dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS)[J]. Eur Heart J,2018,39(3):213-260.
[5]中华医学会心血管病学分会介入心脏病学组,中国医师协会心血管内科医师分会血栓防治专业委员会,中华心血管病杂志编辑委员会. 中国经皮冠状动脉介入治疗指南(2016)[J]. 中华心血管病杂志,2016,44(5):382-400.
[6]Schulz S,Schuster T,Mehilli J,et al. Stent thrombosis after drug-eluting stent implantation:incidence,timing,and relation to discontinuation of clopidogrel therapy over a 4-year period[J]. Eur Heart J,2009,30:2714-2721.
[7]Ducrocq G,Schulte PJ,Becker RC,et al.Association of spontaneous and procedure-related bleeds with short- and long-term mortality after acute coronary syndromes: an analysis from the PLATO trial. EuroIntervention[J]. 2015,11(7):737-745.
[8]Marquis-Gravel G,Dalgaard F,Jones AD,et al. Post-discharge bleeding and mortality following acute coronary syndromes with or without PCI[J]. J Am Coll Cardiol,2020,14,76(2):162-171.
[9]Han YL,Zhang L,Yang LX,et al. A new generation of biodegradable polymer-coated sirolimus-eluting stents for the treatment of coronary artery disease:final 5-year clinical outcomes from the CREATE study[J]. EuroIntervention, 2012 ,22,8(7):815-822.
[10]Vranckx P,Valgimigli M,Jüni P,et al. Ticagrelor plus aspirin for 1 month,followed byticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months,followed by aspirin monotherapy for 12 months after implantation of a drug-elutingstent:a multicentre,open-label,randomised superiority trial[J]. Lancet, 2018 ,15,392(10151):940-949.
[11]Gwon HC,Hahn JY,Park KW,et al. Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents:the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized,multicenter study[J]. Circulation,2012,125(3):505-513.
[12]Schulz-Schüpke S,Byrne RA,Ten Berg JM,et al. ISAR-SAFE:a randomized,double-blind,placebo-controlled trial of 6 vs. 12 months of clopidogrel therapy after drug-eluting stenting[J]. Eur Heart J,2015,36(20):1252-1263.
[13]Hahn JY,Song YB,Oh JH,et al. Effect of P2Y12 Inhibitor monotherapy vs dual antiplatelet therapy on cardiovascular events in patients undergoing percutaneous coronary intervention:the SMART-CHOICE randomized clinical trial[J]. JAMA,2019,25,321(24):2428-2437.
[14]Watanabe H,Domei T,Morimoto T,et al. Effect of 1-month dual antiplatelet therapy followed by clopidogrel vs 12-month dual antiplatelet therapy on cardiovascular and bleeding events in patients receiving PCI:the STOPDAPT-2 randomized clinical trial[J]. JAMA,2019,321(24):2414-2427.
[15]Mehran R,Baber U,Sharma SK,et al. Ticagrelor with or without aspirin in high-risk patients after PCI[J]. N Engl J Med,2019,381(21):2032-2042.
[16]Baber U,Dangas G,Angiolillo DJ,et al. Ticagrelor alone vs. ticagrelor plus aspirin following percutaneous coronary intervention in patients with non-ST-segment elevation acute coronary syndromes:TWILIGHT-ACS[J]. Eur Heart J,2020,41(37):3533-3545.
[17]Dangas G,Baber U,Sharma S,et al. Ticagrelor with or without aspirin after complex PCI[J]. J Am Coll Cardiol,2020,75(19):2414-2424.
[18]Angiolillo DJ,Baber U,Sartori S,et al. Ticagrelor with or without aspirin in high-risk patients with diabetes mellitus undergoing percutaneous coronary intervention[J]. J Am Coll Cardiol,2020,75(19):2403-2413.
[19]Kim BK,Hong SJ,Cho YH,et al. Effect of ticagrelor monotherapy vs ticagrelor with aspirin on major bleeding and cardiovascular events in patients with acute coronary syndrome:The TICO randomized clinical trial[J]. JAMA,2020,323(23):2407-2416.
[20]Collet JP,Thiele H,Barbato E,et al. 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation[J]. Eur Heart J,2020:ehaa575.
相似文献/References:
[1]袁帅,毛玉琳,钱志敏,等.经皮冠脉介入术在高龄老年患者治疗中的研究新进展[J].心血管病学进展,2019,(6):864.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.007]
YUAN Shuai,MAO Yulin,QIAN Zhimin,et al.New Progress in Study of PCI in treatment of Elderly Patients[J].Advances in Cardiovascular Diseases,2019,(4):864.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.007]
[2]陆鑫 张华.无载体含药物洗脱支架研究进展1[J].心血管病学进展,2019,(7):1032.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.017]
LU xinZHANG Hua.Polymer-free Drug-eluting Stent[J].Advances in Cardiovascular Diseases,2019,(4):1032.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.017]
[3]刘丹丹 王海珠 任凤波.ST段抬高型心肌梗死PCI术后血浆微囊泡浓度对再次血运重建的风险预测分析[J].心血管病学进展,2019,(7):1056.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.023]
LIU Dandan,WANG Haizhu,REN Fengbo.Predictive analysis of plasma microvesicles concentration in patients with ST-segment elevation myocardial infarction after target lesion revascularization[J].Advances in Cardiovascular Diseases,2019,(4):1056.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.023]
[4]潘甜 马康华.急性心肌梗死经皮冠脉介入术后冠状动脉无复流的预防和治疗进展[J].心血管病学进展,2019,(5):730.[doi:10.16806/j.cnki.issn.1004-3932019.05.017]
PAN Tian,MA Kanghua.Prevention and Treatment of Coronary Artery No-Reflow after Percutaneous Coronary Intervention in Patients with Acute Myocardial Infarction[J].Advances in Cardiovascular Diseases,2019,(4):730.[doi:10.16806/j.cnki.issn.1004-3932019.05.017]
[5]郑丽娜 范丽华 侯曼.可溶性ST2在STEMI患者经皮冠脉介入术后预后评估中的作用[J].心血管病学进展,2019,(5):827.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.040]
[6]尹涛 陶凌 胡涛.分支技术在冠状动脉慢性完全闭塞病变介入治疗中的应用[J].心血管病学进展,2019,(8):1107.[doi:10.16806/j.cnki.issn.1004-3934.2019.08.009]
YIN Tao,TAO Ling,HU Tao.Application of Branching Techniques in Interventional Treatment of Coronary Chronic Total O cclusion[J].Advances in Cardiovascular Diseases,2019,(4):1107.[doi:10.16806/j.cnki.issn.1004-3934.2019.08.009]
[7]郭云飞 柳景华.冠状动脉慢性完全闭塞合并分叉病变介入治疗[J].心血管病学进展,2020,(1):7.[doi:10.16806/j.cnki.issn.1004-3934.2020.01.003]
GUO Yunfei,LIU Jinghua.Percutaneous Coronary Intervention for Chronic Total Occlusion with Bifurcation Lesions[J].Advances in Cardiovascular Diseases,2020,(4):7.[doi:10.16806/j.cnki.issn.1004-3934.2020.01.003]
[8]徐奕 杨跃进.经桡动脉冠状动脉介入术后骨筋膜室综合征的防治[J].心血管病学进展,2020,(1):1.[doi:10.16806/j.cnki.issn.1004-3934.2020.01.001]
XU Yi,YANG Yuejin.Prevention and Treatment of Osteofascial Compartment Syndrome after Transradial Percutaneous Coronary Intervention[J].Advances in Cardiovascular Diseases,2020,(4):1.[doi:10.16806/j.cnki.issn.1004-3934.2020.01.001]
[9]马琛 陈少敏 崔鸣.冠状动脉慢性完全闭塞病变治疗研究进展[J].心血管病学进展,2020,(4):333.[doi:10.16806/j.cnki.issn.1004-3934.2020.04.001]
MA Chen,CHEN Shaomin,CUI Ming.Treatment in Patients with Coronary Chronic Total Occlusion[J].Advances in Cardiovascular Diseases,2020,(4):333.[doi:10.16806/j.cnki.issn.1004-3934.2020.04.001]
[10]奚云萍 臧雁翔 李为民.临床SYNTAX计分及其衍生计分在冠心病血运重建预后中的应用价值[J].心血管病学进展,2020,(5):452.[doi:10.16806/j.cnki.issn.1004-3934.2020.05.004]
XI Yunping,ZANG Yanxiang,LI Weimin.Value of Clinical SYNTAX Score and Its Derivative Score in Prognosis of Coronary Artery Disease with Revascularization[J].Advances in Cardiovascular Diseases,2020,(4):452.[doi:10.16806/j.cnki.issn.1004-3934.2020.05.004]